Published On : 06 Sep 2016
QYResearchReports.com has recently added a new report to its repertoire of market studies on the pharmaceutical industry. The report is titled “Global Methicillin-Resistant Staphylococcus Aureus (MRSA) Infections Market 2016 Industry, Analysis, Research, Share, Growth, Sales, Trends, Supply, Forecast to 2021,” and is available for sale on the company website. It presents exhaustive detail pertaining to the various factors influencing the methicillin-resistant staphylococcus aureus (MRSA) infections market. The impact of government policies and regulations on the market is studied as well.
Methicillin-resistant staphylococcus aureus infections occur when Staphylococcus aureus bacterium infects any part of the body. High resistance of these pathogens to the commonly used antibiotics such as amoxicillin, methicillin, oxacillin, and penicillin makes the treatment of MRSA infections very difficult. The bacterium mainly infects body parts such as surgical wounds, skin, blood streams, IV, lungs or other sites such as urinary tract through which catheters enter the body. Infections caused due to these bacteria could be life threatening.
MRSA infections called community associated MRSA can spread by casual contact or even through contaminated objects. It may be acquired in healthcare settings and hospitals as well. Such infections are known as healthcare associated MRSA (HA MRSA), which is one of the most common forms of MRSA infections affecting many around the world. These two types of infections are quite different from each other, considering the characteristics of their strains that cause infection and epidemiology. The overuse of potent drugs and antibiotics for less serious infections could also develop MRSA. The symptoms of MRSA differs based on the site of infection and they can diagnosed by laboratory testing.
To get sample copy of report visit @ http://www.qyresearchreports.com/sample/sample.php?rep_id=736479&type=E
The demand for MRSA drugs is expected to rise in the coming years in response to the rising prevalence of MRSA infections. Furthermore, the increasing participation by both government and international agencies to spread awareness about these infections will augment the growth of the market. However, the increasing competition among the key market players to overcome the resistance that pathogens pose to multi-drugs is restraining the market’s growth to an extent.
MRSA can be treated using antibiotics such as vancomycin and Bactrim. However, pathogens have started developing resistance against these drugs too owing to their persistent ability to adapt to novel antibiotics. Other options available for MRSA treatment include generics such as minocycline and clindamycin, and prominent brand names such as Cubicin, Synercid, Tygacil, and Zyvox.
Regionally, North America and Europe have emerged as lucrative markets for MRSA treatment and drugs. The market will also witness attractive opportunities in Asia Pacific and other emerging regions as they accelerate their healthcare spending.
To present a comprehensive overview of the market, the report also profiles companies such as Merck & Co., Inc, Takeda Pharmaceutical Company Limited, Cubist Pharmaceuticals, Inc., GlaxoSmithKline PLC, Pfizer, Inc., AstraZeneca PLC, ViroPharma, Inc., Forest Laboratories, Inc., and Theravance, Inc.